Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 150

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 150
---
 price for the remaining 81% ownership to the total fair value of the GQ Bio Acquisition (in thousands):Fair Value of Purchase Price ConsiderationAmountCash consideration paid at closing$17,604 Indemnification holdback5,676 Cash payment of GQ Bio Acquisition transaction expenses919 Settlement of previously invested note receivable5,322 Settlement of pre-existing receivable1,055 Purchase price consideration of 81% of GQ Bio30,576 Prior 19% equity investment ownership of GQ Bio realized upon business combination8,315 Total fair value of the GQ Bio Acquisition$38,891 The Company has accounted for the GQ Bio Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in its condensed consolidated financial statements from the acquisition date of February 27, 2025. A $5.7 million indemnification holdback established for potential unidentified liabilities will be settled within 18 months from the acquisition date. In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable in GQ Bio were part of the fair value of consideration exchanged. See Note 10, Financial Instruments, for additional information.The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of intangible assets, tangible assets, liabilities and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. 

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 13

The following tables set forth the preliminary allocation of the GQ Bio Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):Amounts Recognized at the Acquisition Date (as Previously Reported) (a)Measurement Period Adjustments (b)Amounts Recognized at the Acquisition Date (as Adjusted)ASSETS ACQUIREDCash and cash equivalents$1,884 $— $1,884 Accounts receivable